In rats with permanent electrodes, mescaline initially caused immediate EEG desynchronization and behavioral arousal lasting 2-3 hours, after which slow wave sleep and REM sleep reappeared. With continued administration every 6 hours, partial tolerance developed, shown by gradually shorter latencies to sleep onset. Rats tolerant to mescaline were cross-tolerant to LSD and DET but not to amphetamine, even though amphetamine produces similar arousal and EEG effects. These findings support the usefulness of EEG as a quantitative measure of central nervous system function and align with behavioral studies of tolerance and cross-tolerance among hallucinogens.
Mescaline, a naturally occurring psychedelic compound, shows promising potential in pharmacology. In a study involving 120 participants, 75% reported significant improvements in mood and anxiety levels after mescaline administration. The chemical synthesis and analysis revealed a strong correlation between dosage and therapeutic effects, with an effect size of 0.6 for mood enhancement. Additionally, biological evaluation highlighted its interaction with serotonin receptors, suggesting profound implications for mental health treatments. These insights bridge chemistry and biology, paving the way for innovative therapeutic approaches.